269 related articles for article (PubMed ID: 19297483)
1. Herd immunity to GII.4 noroviruses is supported by outbreak patient sera.
Cannon JL; Lindesmith LC; Donaldson EF; Saxe L; Baric RS; Vinjé J
J Virol; 2009 Jun; 83(11):5363-74. PubMed ID: 19297483
[TBL] [Abstract][Full Text] [Related]
2. Human Sera Collected between 1979 and 2010 Possess Blocking-Antibody Titers to Pandemic GII.4 Noroviruses Isolated over Three Decades.
Sharma S; Carlsson B; Czakó R; Vene S; Haglund M; Ludvigsson J; Larson G; Hammarström L; Sosnovtsev SV; Atmar RL; Green KY; Estes MK; Svensson L
J Virol; 2017 Jul; 91(14):. PubMed ID: 28468886
[TBL] [Abstract][Full Text] [Related]
3. Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial.
Lindesmith LC; Ferris MT; Mullan CW; Ferreira J; Debbink K; Swanstrom J; Richardson C; Goodwin RR; Baehner F; Mendelman PM; Bargatze RF; Baric RS
PLoS Med; 2015 Mar; 12(3):e1001807. PubMed ID: 25803642
[TBL] [Abstract][Full Text] [Related]
4. Norovirus GII.17 Virus-Like Particles Bind to Different Histo-Blood Group Antigens and Cross-React with Genogroup II-Specific Mouse Sera.
Malm M; Tamminen K; Vesikari T; Blazevic V
Viral Immunol; 2018 Dec; 31(10):649-657. PubMed ID: 30431404
[TBL] [Abstract][Full Text] [Related]
5. Chimeric VLPs with GII.3 P2 domain in a backbone of GII.4 VP1 confers novel HBGA binding ability.
Huo Y; Wang W; Ling T; Wan X; Ding L; Shen S; Huo J; Zhang S; Wang M; Wang Y; Liu Y
Virus Res; 2016 Sep; 224():1-5. PubMed ID: 27521750
[TBL] [Abstract][Full Text] [Related]
6. Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity.
Debbink K; Donaldson EF; Lindesmith LC; Baric RS
J Virol; 2012 Jan; 86(2):1214-26. PubMed ID: 22090110
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of GII.4 norovirus persistence in human populations.
Lindesmith LC; Donaldson EF; Lobue AD; Cannon JL; Zheng DP; Vinje J; Baric RS
PLoS Med; 2008 Feb; 5(2):e31. PubMed ID: 18271619
[TBL] [Abstract][Full Text] [Related]
8. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation.
Lindesmith LC; Beltramello M; Donaldson EF; Corti D; Swanstrom J; Debbink K; Lanzavecchia A; Baric RS
PLoS Pathog; 2012; 8(5):e1002705. PubMed ID: 22615565
[TBL] [Abstract][Full Text] [Related]
9. Norovirus infections and seroprevalence of genotype GII.4-specific antibodies in a Spanish population.
Carmona-Vicente N; Fernández-Jiménez M; Ribes JM; Téllez-Castillo CJ; Khodayar-Pardo P; Rodríguez-Diaz J; Buesa J
J Med Virol; 2015 Apr; 87(4):675-82. PubMed ID: 25655810
[TBL] [Abstract][Full Text] [Related]
10. Human Norovirus Neutralized by a Monoclonal Antibody Targeting the Histo-Blood Group Antigen Pocket.
Koromyslova AD; Morozov VA; Hefele L; Hansman GS
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541855
[TBL] [Abstract][Full Text] [Related]
11. Antigenic Relatedness of Norovirus GII.4 Variants Determined by Human Challenge Sera.
Dai YC; Zhang XF; Xia M; Tan M; Quigley C; Lei W; Fang H; Zhong W; Lee B; Pang X; Nie J; Jiang X
PLoS One; 2015; 10(4):e0124945. PubMed ID: 25915764
[TBL] [Abstract][Full Text] [Related]
12. Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity.
Debbink K; Lindesmith LC; Donaldson EF; Costantini V; Beltramello M; Corti D; Swanstrom J; Lanzavecchia A; Vinjé J; Baric RS
J Infect Dis; 2013 Dec; 208(11):1877-87. PubMed ID: 23908476
[TBL] [Abstract][Full Text] [Related]
13. Phylogenetic and biological characterizations of a GI.3 norovirus.
Zheng L; Zhang H; Ma J; Liu J; Ma S; Wang M; Huo Y
Infect Genet Evol; 2020 Nov; 85():104554. PubMed ID: 32927119
[TBL] [Abstract][Full Text] [Related]
14. Norovirus GII.4 strain antigenic variation.
Lindesmith LC; Donaldson EF; Baric RS
J Virol; 2011 Jan; 85(1):231-42. PubMed ID: 20980508
[TBL] [Abstract][Full Text] [Related]
15. Genomic and biological characterization of a pandemic norovirus variant GII.4 Sydney 2012.
Ge L; Chen X; Liu J; Zheng L; Chen C; Luo S; Guo P; Kong J; Song Y; Huo Y
Virus Genes; 2020 Apr; 56(2):174-181. PubMed ID: 31912284
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Antigenic Relatedness between GII.4 and GII.17 Noroviruses by Use of Serum Samples from Norovirus-Infected Patients.
Dai YC; Xia M; Huang Q; Tan M; Qin L; Zhuang YL; Long Y; Li JD; Jiang X; Zhang XF
J Clin Microbiol; 2017 Dec; 55(12):3366-3373. PubMed ID: 28904188
[TBL] [Abstract][Full Text] [Related]
17. Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes.
Lindesmith LC; Costantini V; Swanstrom J; Debbink K; Donaldson EF; Vinjé J; Baric RS
J Virol; 2013 Mar; 87(5):2803-13. PubMed ID: 23269783
[TBL] [Abstract][Full Text] [Related]
18. Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes.
Malm M; Tamminen K; Heinimäki S; Vesikari T; Blazevic V
Vaccine; 2018 Jan; 36(4):484-490. PubMed ID: 29246474
[TBL] [Abstract][Full Text] [Related]
19. Induction of homologous and cross-reactive GII.4-specific blocking antibodies in children after GII.4 New Orleans norovirus infection.
Blazevic V; Malm M; Vesikari T
J Med Virol; 2015 Oct; 87(10):1656-61. PubMed ID: 25946711
[TBL] [Abstract][Full Text] [Related]
20. Biological and immunological characterization of norovirus major capsid proteins from three different genotypes.
Huo Y; Wan X; Ling T; Shen S
Microb Pathog; 2016 Jan; 90():78-83. PubMed ID: 26616166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
